Kane MAC, Brandt F, Rohrich RJ, Narins RS, Monheit GD, Huber MB; Reloxin Investigational Group. Evaluation of variable-dose treatment with a new U.S. Botulinum Toxin Type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase III, randomized, double-blind, placebo-controlled study. Plast Reconstr Surg. 2009 Nov;124(5):1619-1629.

Schlessinger J, Monheit G, Kane MA, Mendelsohn N. Time to onset of response of abobotulinumtoxina in the treatment of glabellar lines: a subset analysis of phase 3 clinical trials of a new botulinum toxin type A. Dermatol Surg. 2011 Oct;37(10):1434-42.

Brandt F, Swanson N, Baumann L, Huber B. Randomized, placebo-controlled study of a new botulinum toxin type a for treatment of glabellar lines: efficacy and safety. Dermatol Surg. 2009 Dec;35(12):1893-901.

Moy R, Maas C, Monheit G, Huber MB; Reloxin Investigational Group. Long-term safety and efficacy of a new botulinum toxin type A in treating glabellar lines. Arch Facial Plast Surg. 2009 Mar-Apr;11(2):77-83.

Kassir R, Kolluru A, Kassir M. Triple-Blind, Prospective, Internally Controlled Comparative Study Between AbobotulinumtoxinA and OnabotulinumtoxinA for the Treatment of Facial Rhytids. Dermatol Ther (Heidelb). 2013 Dec;3(2):179-89.

Dysport Summary of Product Characteristics, Galderma, July 2018.

Monheit GD, Baumann L, Maas C, Rand R, Down R. Efficacy, Safety, and Subject Satisfaction After AbobotulinumtoxinA Treatment for Moderate to Severe Glabellar Lines. Dermatol Surg. 2020 Jan;46(1):61-69.

Rzany B, Dill-Müller D, Grablowitz D, Heckmann M, Caird D; German-Austrian Retrospective Study Group. Repeated botulinum toxin A injections for the treatment of lines in the upper face: a retrospective study of 4,103 treatments in 945 patients. Dermatol Surg. 2007 Jan;33(1 Spec No.):S18-25.

Gubanova E, Haddad Tabet M, Bergerova Y, Moiseieva O, Chemeris A, Sanches E, Sharova A, Rodriguez Pose L, Raymond R, Prygova I, Carlisle I. Assessment of Subject and Physician Satisfaction after Long-Term Treatment of Glabellar Lines with AbobotulinumtoxinA (Dysport®/Azzalure®): Primary Results of the APPEAL Noninterventional Study. Aesthetic Plast Surg. 2018 Dec;42(6):1672-1680. 

Field M, Splevins A, Picaut P, van der Schans M, Langenberg J, Noort D, et al. AbobotulinumtoxinA (Dysport®), OnabotulinumtoxinA (Botox®), and IncobotulinumtoxinA (Xeomin®) Neurotoxin Content and Potential Implications for Duration of Response in Patients. Toxins. 2018 Dec 13;10(12):535. 

Schlessinger J, Cohen JL, Shamban A, Jacob C, Karimi K, Maas C, Lane V, Coquis-Knezek S, Meckfessel M. A Multicenter Study to Evaluate Subject Satisfaction With Two Treatments of AbobotulinumtoxinA a Year in the Glabellar Lines. Dermatol Surg. 2021 Apr 1;47(4):504-509. 

Schlessinger J, Dover JS, Joseph J, Monheit G, Nelson DB, Albright CD, Axford-Gatley RA, Cohen JL; Dysport Study Group. Long-term safety of abobotulinumtoxinA for the treatment of glabellar lines: results from a 36-month, multicenter, open-label extension study. Dermatol Surg. 2014 Feb;40(2):176-83.

Pickett A, and Keren Perrow. Formulation composition of Botulinum Toxins in Clinical Use. J Drugs Dermatol. 2010 Sep:9 (9):1085-1091